Abstract
Hematopoietic growth factors (HGF) such as G-CSF and GM-CSF stimulate cell growth of the bone marrow and thereby mitigate the myelotoxic effect of chemotherapy. Using 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) for therapy response monitoring of patients with small-cell lung cancer, both an extension and an intensification of thoracic bone marrow uptake were noted in patients treated with HGF (n = 5) compared to those patients without HGF supplementation (n = 11). FDG uptake was a very sensitive marker of stimulated hematopoiesis, and both the extension and the intensification of uptake have to be noted during HGF therapy.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Bone Marrow / diagnostic imaging
-
Bone Marrow / drug effects*
-
Bone Marrow / metabolism*
-
Carcinoma, Small Cell / drug therapy
-
Deoxyglucose / analogs & derivatives*
-
Deoxyglucose / pharmacokinetics
-
Double-Blind Method
-
Female
-
Fluorine Radioisotopes*
-
Fluorodeoxyglucose F18
-
Hematopoietic Cell Growth Factors / therapeutic use*
-
Humans
-
Lung Neoplasms / drug therapy
-
Male
-
Middle Aged
-
Prospective Studies
-
Tomography, Emission-Computed
Substances
-
Antineoplastic Agents
-
Fluorine Radioisotopes
-
Hematopoietic Cell Growth Factors
-
Fluorodeoxyglucose F18
-
Deoxyglucose